{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T05:13:04Z","timestamp":1777093984709,"version":"3.51.4"},"reference-count":20,"publisher":"Archives of Endocrinology and Metabolism","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,16]]},"DOI":"10.20945\/2359-4292-2024-0023","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T16:17:11Z","timestamp":1734365831000},"source":"Crossref","is-referenced-by-count":2,"title":["Characterization of adult patients with X-linked hypophosphatemia at a specialized center in Buenos Aires, Argentina"],"prefix":"10.20945","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3694-8357","authenticated-orcid":false,"given":"Evangelina","family":"Giacoia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9795-4918","authenticated-orcid":false,"given":"Laura Mar\u00eda","family":"Schir\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5855-5459","authenticated-orcid":false,"given":"Tatiana","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2231-7260","authenticated-orcid":false,"given":"Mar\u00eda Celeste","family":"Balonga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8528-3938","authenticated-orcid":false,"given":"Luisa","family":"Plantalech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8510","reference":[{"issue":"1","key":"key20241216161709_B1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11154-017-9408-1","article-title":"X-linked hypophosphatemia and growth","volume":"18","author":"Fuente","year":"2017","unstructured":"Fuente R, Gil-Pe\u00f1a H, Claramunt-Taberner D, Hern\u00e1ndez O, Fern\u00e1ndez-Iglesias A, Alonso-Dur\u00e1n L, et al. X-linked hypophosphatemia and growth. Rev Endocr Metab Disord. 2017;18(1):107-15. doi: 10.1007\/s11154-017-9408-1.","journal-title":"Rev Endocr Metab Disord"},{"key":"key20241216161709_B2","doi-asserted-by":"crossref","first-page":"641543","DOI":"10.3389\/fendo.2021.641543","article-title":"Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium","volume":"12","author":"Laurent","year":"2021","unstructured":"Laurent MR, De Schepper J, Trouet D, Godefroid N, Boros E, Heinrichs C, et al. Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium. Front Endocrinol (Lausanne). 2021;12:641543. doi: 10.3389\/fendo.2021.641543.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"key20241216161709_B3","first-page":"S021169952300070X","article-title":"Hipofosfatemia ligada al cromosoma X: resultado a largo plazo con diferentes modalidades de tratamiento","author":"Alconcher","year":"2023","unstructured":"Alconcher L, Lucarelli L, Bronfen S. Hipofosfatemia ligada al cromosoma X: resultado a largo plazo con diferentes modalidades de tratamiento. Nefrolog\u00eda. 2023;S021169952300070X. doi: 10.1016\/j.nefro.2023.05.001.","journal-title":"Nefrolog\u00eda"},{"issue":"1","key":"key20241216161709_B4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","article-title":"FGF23 and its role in X-linked hypophosphatemia-related morbidity","volume":"14","author":"Beck-Nielsen","year":"2019","unstructured":"Beck-Nielsen SS, Mughal Z, Haffner D, Nilsson O, Levtchenko E, Ariceta G, et al. FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J Rare Dis. 2019;14(1):58. doi: 10.1186\/s13023-019-1014-8.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"key20241216161709_B5","doi-asserted-by":"crossref","first-page":"176","DOI":"10.17294\/2330-0698.1727","article-title":"Giving Credence to the Experience of X-Linked Hypophosphatemia in Adulthood: An Interprofessional Mixed-Methods Study","volume":"7","author":"Hughes","year":"2020","unstructured":"Hughes M, Macica C, Meriano C, Doyle M. Giving Credence to the Experience of X-Linked Hypophosphatemia in Adulthood: An Interprofessional Mixed-Methods Study. J Patient Cent Res Rev. 2020;7(2):176-88. doi: 10.17294\/2330-0698.1727.","journal-title":"J Patient Cent Res Rev"},{"issue":"1","key":"key20241216161709_B6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00198-020-05548-0","article-title":"Burden of disease associated with X-linked hypophosphataemia in adults: a systematic literature review","volume":"32","author":"Seefried","year":"2021","unstructured":"Seefried L, Smyth M, Keen R, Harvengt P. Burden of disease associated with X-linked hypophosphataemia in adults: a systematic literature review. Osteoporos Int. 2021;32(1):7-22. doi: 10.1007\/s00198-020-05548-0.","journal-title":"Osteoporos Int"},{"issue":"12","key":"key20241216161709_B7","first-page":"1833","article-title":"Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee","volume":"15","author":"Bellamy","year":"1988","unstructured":"Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15(12):1833-40.","journal-title":"J Rheumatol"},{"issue":"1","key":"key20241216161709_B8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s41687-020-0181-7","article-title":"Development and validation of an interpretive guide for PROMIS scores","volume":"4","author":"Rothrock","year":"2020","unstructured":"Rothrock NE, Amtmann D, Cook KF. Development and validation of an interpretive guide for PROMIS scores. J Patient Rep Outcomes. 2020;4(1):16. doi: 10.1186\/s41687-020-0181-7.","journal-title":"J Patient Rep Outcomes"},{"issue":"12","key":"key20241216161709_B9","doi-asserted-by":"crossref","first-page":"1279.e6","DOI":"10.1016\/j.jclinepi.2008.05.004","article-title":"The Argentine-Spanish SF-36 Health Survey was successfully validated for local outcome research","volume":"61","author":"Augustovski","year":"2008","unstructured":"Augustovski FA, Lewin G, Garc\u00eda-Elorrio E, Rubinstein A. The Argentine-Spanish SF-36 Health Survey was successfully validated for local outcome research. J Clin Epidemiol. 2008;61(12):1279-84.e6. doi: 10.1016\/j.jclinepi.2008.05.004.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"key20241216161709_B10","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/pubmed\/fdr006","article-title":"Short Form 36 (SF-36) Health Survey Questionnaire: normative data for Wales. Journal of Public Health","volume":"33","author":"Burholt","year":"2011","unstructured":"Burholt V, Nash P. Short Form 36 (SF-36) Health Survey Questionnaire: normative data for Wales. Journal of Public Health. J Public Health (Oxf). 2011;33(4):587-603. doi: 10.1093\/pubmed\/fdr006.","journal-title":"J Public Health (Oxf)"},{"issue":"7","key":"key20241216161709_B11","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.arcped.2021.09.002","article-title":"Contribution of imaging to the diagnosis and follow up of X-linked hypophosphatemia","volume":"28","author":"Adamsbaum","year":"2021","unstructured":"Adamsbaum C, Laredo JD, Briot K, Linglart A. Contribution of imaging to the diagnosis and follow up of X-linked hypophosphatemia. Arch Pediatr. 2021;28(7):594-8. doi: 10.1016\/j.arcped.2021.09.002.","journal-title":"Arch Pediatr"},{"issue":"3","key":"key20241216161709_B12","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3390\/endocrines3030030","article-title":"Adult Presentation of X-Linked Hypophosphatemia","volume":"3","author":"Ito","year":"2022","unstructured":"Ito N. Adult Presentation of X-Linked Hypophosphatemia. Endocrines 2022;3(3):375-90. doi: 10.3390\/endocrines3030030.","journal-title":"Endocrines"},{"issue":"9","key":"key20241216161709_B13","doi-asserted-by":"crossref","first-page":"e3682","DOI":"10.1210\/clinem\/dgab282","article-title":"Incidence of Complications in 25 Adult Patients With X-linked Hypophosphatemia","volume":"106","author":"Kato","year":"2021","unstructured":"Kato H, Koga M, Kinoshita Y, Taniguchi Y, Kobayashi H, Fukumoto S, et al. Incidence of Complications in 25 Adult Patients With X-linked Hypophosphatemia. J Clin Endocrinol Metab. 2021;106(9):e3682-92. doi: 10.1210\/clinem\/dgab282.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"key20241216161709_B14","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s00198-021-05997-1","article-title":"Burden of disease and clinical targets in adult patients with X-linked hypophosphatemia. A comprehensive review","volume":"32","author":"Giannini","year":"2021","unstructured":"Giannini S, Bianchi ML, Rendina D, Massoletti P, Lazzerini D, Brandi ML. Burden of disease and clinical targets in adult patients with X-linked hypophosphatemia. A comprehensive review. Osteoporos Int. 2021;32(10):1937-49. doi: 10.1007\/s00198-021-05997-1.","journal-title":"Osteoporos Int"},{"issue":"3","key":"key20241216161709_B15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/EJE-15-0661","article-title":"Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms","volume":"174","author":"Che","year":"2016","unstructured":"Che H, Roux C, Etcheto A, Rothenbuhler A, Kamenicky P, Linglart A, et al. Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms. Eur J Endocrinol. 2016;174(3):325-33. doi: 10.1530\/EJE-15-0661.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"key20241216161709_B16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13023-023-02620-w","article-title":"Patient-reported outcomes measures of X-linked hypophosphataemia participants: findings from a prospective cohort study in the UK","volume":"18","author":"Cole","year":"2023","unstructured":"Cole S, Sanchez-Santos MT, Kolovos S, Javaid MK, Pinedo-Villanueva R. Patient-reported outcomes measures of X-linked hypophosphataemia participants: findings from a prospective cohort study in the UK. Orphanet J Rare Dis. 2023;18(1):26. doi: 10.1186\/s13023-023-02620-w.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"key20241216161709_B17","doi-asserted-by":"crossref","first-page":"152.e1","DOI":"10.1016\/j.medcli.2021.07.029","article-title":"Clinical practice recommendations for the diagnosis and treatment of X-linked hypophosphatemia: A consensus based on the ADAPTE method","volume":"159","author":"Gonz\u00e1lez-Lamu\u00f1o","year":"2022","unstructured":"Gonz\u00e1lez-Lamu\u00f1o D, Lorente Rodr\u00edguez A, Luis Yanes MI, Mar\u00edn-del Barrio S, Mart\u00ednez D\u00edaz-Guerra G, Peris P. Clinical practice recommendations for the diagnosis and treatment of X-linked hypophosphatemia: A consensus based on the ADAPTE method. Med Clin (Barc). 2022;159(3):152.e1-e12. doi: 10.1016\/j.medcli.2021.07.029.","journal-title":"Med Clin (Barc)"},{"issue":"6","key":"key20241216161709_B18","first-page":"e22","article-title":"Effect of medication dosing frequency on adherence in chronic diseases","volume":"15","author":"Saini","year":"2009","unstructured":"Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15(6):e22-33.","journal-title":"Am J Manag Care"},{"issue":"5","key":"key20241216161709_B19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41573-023-00670-0","article-title":"Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems","volume":"22","author":"Baryakova","year":"2023","unstructured":"Baryakova TH, Pogostin BH, Langer R, McHugh KJ. Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems. Nat Rev Drug Discov. 2023;22(5):387-409. doi: 10.1038\/s41573-023-00670-0.","journal-title":"Nat Rev Drug Discov"},{"issue":"21","key":"key20241216161709_B20","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab Therapy in Children with X-Linked Hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","unstructured":"Carpenter TO, Whyte MP, Imel EA, Boot AM, H\u00f6gler W, Linglart A, et al. Burosumab Therapy in Children with X-Linked Hypophosphatemia. N Engl J Med. 2018;378(21):1987-98. doi: 10.1056\/NEJMoa1714641.","journal-title":"N Engl J Med"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T16:17:20Z","timestamp":1734365840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aem-sbem.com\/article\/characterization-of-adult-patients-with-x-linked-hypophosphatemia-at-a-specialized-center-in-buenos-aires-argentina\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":20,"alternative-id":["10.20945\/2359-4292-2024-0023"],"URL":"https:\/\/doi.org\/10.20945\/2359-4292-2024-0023","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"value":"2359-3997","type":"print"},{"value":"2359-4292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"e240023"}}